SRS, also known as Piscirickettsiosis, is caused by the bacterium Piscirickettsia salmonis, generating a severe disease that has caused major economic losses in the aquaculture industry since its appearance in 1989. The disease is affecting all three species farmed in Chile: Atlantic salmon, rainbow trout and coho salmon.
"Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable and reliable fish production,” said the president of Pharmaq, Morten K Nordstad.
The approval from the Chilean authority (SAG) to sell the attenuated live vaccine is a major technology milestone for the fish farming industry and for Pharmaq. Behind this product are many years of research, development and documentation to ensure a high quality product that provides a high level of protection as well as being safe for the fish and the environment, said the company.